Delek Group Ltd. Acquires Shares of 65,919 Versartis (VSAR)

Delek Group Ltd. acquired a new stake in Versartis (NASDAQ:VSAR) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 65,919 shares of the biopharmaceutical company’s stock, valued at approximately $145,000. Delek Group Ltd. owned approximately 0.18% of Versartis as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC increased its holdings in Versartis by 1.7% in the second quarter. Parametric Portfolio Associates LLC now owns 32,597 shares of the biopharmaceutical company’s stock valued at $569,000 after buying an additional 535 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Versartis by 4.8% in the second quarter. The Manufacturers Life Insurance Company now owns 26,326 shares of the biopharmaceutical company’s stock valued at $459,000 after purchasing an additional 1,204 shares during the period. State Street Corp grew its position in shares of Versartis by 6.9% in the second quarter. State Street Corp now owns 556,718 shares of the biopharmaceutical company’s stock valued at $9,716,000 after purchasing an additional 35,957 shares during the period. Deutsche Bank AG grew its position in shares of Versartis by 90.0% in the fourth quarter. Deutsche Bank AG now owns 82,299 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 38,975 shares during the period. Finally, Orbimed Advisors LLC acquired a new stake in shares of Versartis in the third quarter valued at about $123,000. 48.52% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Several analysts have recently issued reports on VSAR shares. Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research report on Sunday, January 21st. Canaccord Genuity lowered shares of Versartis from a “buy” rating to a “hold” rating and dropped their target price for the company from $9.00 to $5.00 in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $5.13.

In related news, insider Jay Shepard sold 14,446 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $1.80, for a total transaction of $26,002.80. Following the transaction, the insider now directly owns 602,298 shares in the company, valued at $1,084,136.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 21,400 shares of company stock worth $38,520 over the last 90 days. 10.90% of the stock is currently owned by company insiders.

Shares of VSAR stock opened at $1.65 on Friday. Versartis has a 52-week low of $1.55 and a 52-week high of $22.30. The stock has a market cap of $64.46, a PE ratio of -0.68 and a beta of 2.21. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.61 and a quick ratio of 14.62.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $1.78. The business had revenue of $0.04 million for the quarter. sell-side analysts forecast that Versartis will post -3.15 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Delek Group Ltd. Acquires Shares of 65,919 Versartis (VSAR)” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3295293/delek-group-ltd-acquires-shares-of-65919-versartis-vsar.html.

About Versartis

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

China Life Insurance  versus Its Rivals Head to Head Analysis
China Life Insurance versus Its Rivals Head to Head Analysis
Analysts Expect BeiGene  Will Post Earnings of -$1.96 Per Share
Analysts Expect BeiGene Will Post Earnings of -$1.96 Per Share
Zacks: Analysts Anticipate Clementia Pharmaceuticals  Will Post Earnings of -$0.33 Per Share
Zacks: Analysts Anticipate Clementia Pharmaceuticals Will Post Earnings of -$0.33 Per Share
1347 PIH  Receiving Somewhat Positive Media Coverage, Accern Reports
1347 PIH Receiving Somewhat Positive Media Coverage, Accern Reports
Good Times Burgers & Frozen Custard  Getting Somewhat Favorable Press Coverage, Analysis Finds
Good Times Burgers & Frozen Custard Getting Somewhat Favorable Press Coverage, Analysis Finds
First Community Co. to Issue Quarterly Dividend of $0.10
First Community Co. to Issue Quarterly Dividend of $0.10


© 2006-2018 Ticker Report. Google+.